Shanxi Sanjiu Tongda Pharmaceutical Co. Ltd.

Primary objective: To evaluate the bioequivalence of febuxostat tablets (trade name: Feburic®) (40 mg) licensed by Teijin Pharma Limited as the reference formulation and febuxostat tablets (40 mg) licensed by Shanxi Tongda Pharmaceutical Co., Ltd. as the test formulation in a single-center, randomized, open-label, single-dose, two-period, two-sequence, two-crossover clinical trial in fasting individuals. Secondary objective: To observe the safety of the test and reference formulations in healthy participants in a Chinese trial.

Primary Objective: To investigate the pharmacokinetics of a single oral dose of the test formulation, esomeprazole magnesium enteric-coated capsules (40 mg, provided by Shanxi Tongda Pharmaceutical Co., Ltd.), and the reference formulation, esomeprazole magnesium enteric-coated capsules (NEXIUM®, 40 mg; licensee: AstraZeneca Pharmaceuticals LP), in healthy adult participants under fasting and fasting (apple jam) conditions, and to evaluate the bioequivalence of the two formulations under fasting and fasting (apple jam) conditions. Secondary Objective: To evaluate the safety of the test formulation, esomeprazole magnesium enteric-coated capsules, and the reference formulation, esomeprazole magnesium enteric-coated capsules (NEXIUM®), in healthy adult participants under fasting and fasting (apple jam) conditions.

Primary objective: To evaluate the bioequivalence of epinastine hydrochloride tablets (licensed by Shanxi Tongda Pharmaceutical Co., Ltd.) in humans under fasting and postprandial conditions through a single-center, randomized, open-label, single-dose, two-formulation, two-sequence, two-period, double-crossover clinical trial, using epinastine hydrochloride tablets (trade name: Alesion, 20 mg) licensed by Nippon Boehringer Ingelheim Co., Ltd. as the reference formulation. Secondary objective: To observe the safety of the test and reference formulations in Chinese health study participants.